Polatuzumab is a monoclonal antibody directed against CD79b, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab can be used in the synthesis of polatuzumab vedotin, an ADC indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).